Streetbeat News

KNBIF

Kane Biotech Inc.

Industry

Research and Development in Biotechnology

Open

0.08

Mkt cap

11M

Volume

32K

High

0.08

P/E Ratio

2.00

52-wk high

0.12

Low

0.08

Div yield

N/A

52-wk low

0.04

Kane Biotech Inc. announced a non-brokered private placement offering of up to 30 million common shares at $0.10 per share, aiming to raise $3 million.

Portfolio Pulse from

December 03, 2024 | 1:45 pm

Kane Biotech Inc. reported its third quarter 2024 financial results, highlighting a significant increase in product sales to $597,677 from $3,631 in the same period last year, excluding discontinued operations.

Portfolio Pulse from

November 28, 2024 | 9:30 pm

Kane Biotech Inc. is set to release its third quarter 2024 financial results on November 28, 2024, after market close. A conference call will follow at 4:30 p.m.

Portfolio Pulse from

November 21, 2024 | 9:45 pm

Kane Biotech Inc. has received Health Canada approval for its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device, potentially boosting its market presence and sales.

Portfolio Pulse from

November 14, 2024 | 6:30 pm

Kane Biotech has provided an investor update following the announcement of its acquisition of FB Dermatology. The company's leadership, including President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga, discussed the strategic opportunity this acquisition presents.

Portfolio Pulse from

November 14, 2024 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.